Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

20-06-2015 | Uitgave 1/2016

Quality of Life Research 1/2016

Turkish version of the Drug Hypersensitivity Quality of Life Questionnaire: assessment of reliability and validity

Tijdschrift:
Quality of Life Research > Uitgave 1/2016
Auteurs:
Sevim Bavbek, Seçil Kepil Özdemir, Beyza Doğanay Erdoğan, Işıl Karaboğa, Suna Büyüköztürk, Aslı Gelincik, İnsu Yılmaz, Özlem Göksel, Adile Berna Dursun, Gül Karakaya, Ali Fuat Kalyoncu, Ferhan Özşeker, Gülden Paşaoğlu Karakış, Ferda Öner Erkekol, Gözde Köycü, Metin Keren, Ilaria Baiardini, Antonino Romano

Abstract

Purpose

The first disease-specific quality-of-life questionnaire in patients with drug hypersensitivity, Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q), was developed and validated recently. The aim of this study was to assess validity, reliability and responsiveness to interventions of the Turkish version of the DrHy-Q.

Methods

The Turkish version of the DrHy-Q was administered to prospectively enrolled 736 patients with drug hypersensitivity from ten allergy units. To assess validity, all patients completed the validated Turkish version of Psychological General Well-Being Index (PGWBI). For test–retest reliability, 182 patients completed the DrHy-Q 1 week after the first questionnaire administration without any intervention. Responsiveness was assessed on 97 patients who had a DrHy-Q recorded at a follow-up visit after the intervention.

Results

The internal consistency and test–retest reliability of the scale were adequate (Cronbach’s alpha = 0.934, intra-class correlation coefficient = 0.783). The DrHy-Q scores showed weak negative correlations with the PGWBI total and domain scores (r = − 0.378 to −0.254, p < 0.001). DrHy-Q was able to discriminate the patients with one drug hypersensitivity reaction from the patients with two and above two reactions (p = 0.012 and p < 0.001, respectively), and the patients who experienced a respiratory reaction from the patients who did not (p = 0.018). However, it did not discriminate the patients with comorbid disease including psychiatric comorbidity (p > 0.05). The baseline DrHy-Q scores were significantly higher than the post-intervention scores (p = 0.008).

Conclusion

The Turkish version of DrHy-Q is reliable and valid for evaluating quality of life in patients with drug hypersensitivity, and it appeared responsive to interventions.

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Literatuur
Over dit artikel

Andere artikelen Uitgave 1/2016

Quality of Life Research 1/2016 Naar de uitgave